Skip to main content
. 2016 Sep 6;113(38):10666–10671. doi: 10.1073/pnas.1611481113

Table S2.

Apoptotic array

KLM1 RH16 KLM1 RH16
Symbol Act D RG7787 Comb Act D RG7787 Comb Symbol Act D RG7787 Comb Act D RG7787 Comb
Abl 1 1.1 0.9 0.8 1 1.1 CRADD 0.7 2.1 0.7 0.7 1.5 0.8
Aif 1.8 1.8 2.3 0.9 1 1.1 cyt-c 1.8 0.7 2.2 1.5 1.1 1
akt1 1.3 1.1 1 0.8 0.8 0.8 DAPK1 0.6 1.5 0.6 0.5 1.7 0.8
apaf-1 1.3 0.6 0.7 1.8 1 1.9 DFFA 1.5 1 1.2 1.2 0.9 1.3
Bad 1.7 2.2 1.7 0.7 0.8 0.7 Diablo 1.8 2.9 2.8 1 1.1 1.4
bag-1 1.1 0.6 0.7 1.2 0.8 1.1 FADD 1.5 2.1 1.1 0.8 1.2 1.1
bag-3 0.9 1.2 1.4 1.3 1 1.7 Fas 1.1 2.4 1 5.9 0.1 6.1
Bak 1.2 1.6 0.9 1.3 0.7 1.4 Fas-ligand 1.1 0.7 1.6
Bax 1.5 1.3 1.6 1.4 0.7 1.7 GADD45A 4.1 63.1 30 4.5 4.1 21.2
Bcl-10 2.2 4.3 3.2 2.3 1.9 3.9 Harakiri 1.2 1.1 0.9 2.4 3.1 2.2
Bcl-2 2.2 0.6 0.4 0.7 0.9 0.3 IGF1R 0.7 2.6 0.8 0.7 0.9 0.8
BCL2A1 3.4 7.4 21.6 2.1 19.2 22.6 IL10 1.1 0.7 3.3
Bcl-xL 2.7 2.2 1.2 1.3 1 1.7 Mcl-1 1.4 1.1 0.6 1.7 1.1 1.8
Bcl-B 1.8 0.7 0.5 0.4 0.3 0.8 NAIP 0.5 0.9 0.5 1.4 0.8 0.8
Bim 3.1 0.7 2.3 1.8 0.7 1.7 NFkB 1.6 8.5 3.2 1.1 3.2 2.1
Bcl-w 1.4 1.4 1.7 1.3 1.2 1.1 NOD1 0.9 0.5 0.2 0.9 0.7 0.6
Bfar 1.4 1.6 1.1 0.7 0.8 0.8 NOL3 1.9 0.8 1.4 2 0.5 1.2
Bid 1.2 0.9 1.4 0.9 0.8 1 PYCARD 1.1 0.6 0.6 1.3 0.6 1.2
Bik 1.8 6.1 3.6 2.5 1.1 4.1 RIPK2 2.3 2.9 2.2 3.1 2.4 4.8
Birc2 1.5 2.5 1.9 3.1 1.5 2.1 TNF-α 10 147.6 103.1 1.2 6.9 11.2
CIAP 4.7 46.3 13.2 8.6 5.7 9.8 TNF-β 1.2 7.5 13.4 4.8 2.9 3.5
Birc5 2 1 3.2 0.2 0.6 0.3 TNFR3 1.4 1.3 1.2 2.4 0.8 2.2
Birc6 0.6 2.6 0.8 1.9 1.8 1.2 TRAILR1 1.7 1.9 1.4 1.7 0.9 3.4
Bnip-2 1.6 0.9 0.9 2.5 1.2 1.4 TRAILR2 2.7 8.3 4.6 2 1 3.9
Bnip-3 0.6 0.7 0.6 1.8 0.9 2.2 TNFRSF11B 2 0.5 0.6 0.6 4.1 2.2
Bnip-3L 1.3 0.4 1 3.7 1.2 2.2 TNFR1 0.9 1.3 0.7 0.7 0.7 0.9
Braf 0.8 2 0.9 1.6 1.6 1.5 TNFR2 10.5 15.5 8.1 0.5 0.6 0.4
Caspase-1 0.7 0.3 0.4 15 1.3 13.5 TNFRSF21 0.9 0.4 0.5 1.3 1.2 2
Caspase-10 2.1 1.9 3 3.6 1.5 5.4 TNFRSF25 1.1 0.5 0.2 2.6 0.6 1.4
Caspase-14 1.1 0.7 0.5 CD137 4.6 68.8 15.7 0.7 4.5 2.8
Caspase-2 1.6 1 1.5 0.9 1.1 0.7 TNFSF10 0.7 0.1 0.2 0.9 0.5 1
Caspase-3 2.9 1.4 3.8 1.8 1.6 2.4 TNFSF8 0.4 0.9 1
Caspase-4 2 0.9 1.5 2.9 0.9 2.1 TP53 2.4 5.6 8.8 1.5 1.1 1.6
Caspase-5 2.8 0.7 5.6 2.8 1.3 3.5 TP53BP2 1.6 5.8 3.7 1.6 1.7 1.8
Caspase-6 1.3 0.6 1.1 1.1 0.8 1.1 TP73 0.4 1.3 1.1 0.5 3.4 0.3
Caspase-7 3.4 1.1 2.2 1.2 0.9 1.8 TRADD 1.2 0.4 0.5 0.9 1 1.8
Caspase-8 1.7 1.1 1.1 2 0.9 1.3 TRAP 0.9 3.5 1.5 0.5 1.1 0.5
Caspase-9 1.9 2.4 3.2 1 3.4 2.4 TRAF3 0.9 3.8 1 0.7 1.1 0.8
CD27 3.4 0.2 6.2 2.4 0.5 1.8 XIAP 1.1 1.4 0.6 2.7 1.7 2.1
CD40 1.6 1.5 1.3 ACTB 1.4 1.8 1.8 1 1 0.9
CD40LG 1.1 0.7 1.1 1.2 0.5 0.6 B2M 2.3 1.7 2.4 1.7 1.2 1.5
CD70 2.7 4.1 3.3 1.6 1 2.8 GAPDH 1.9 1.4 1.8 1.1 0.9 1.2
Casper 1.8 2.9 2.5 1.7 1.5 2 HPRT1 1 1 1 0.5 1.1 0.6
CIDEA 1.1 1.1 1.2 2 2.6 0.6 RPLP0 1.1 1 1.2 1.1 0.8 1.1
CIDEB 1.3 1.1 1.5 1.2 0.9 1

KLM1 cells were treated with Act D 10 ng/mL with or without 100 ng/mL RG7787 or RH16 cells were treated with Act D at 5 ng/mL and RG7787 (200 ng/mL) for 24 h. Total RNA was extracted, and reverse transcription and real-time PCR were performed with an apoptotic array kit (Qiagen). The numbers are generated using web-based data analysis (Qiagen) by setting the untreated control as 1 and using ACTB, B2M, GAPDH, HPRT1, and RPLP0 as internal controls.